Spots Global Cancer Trial Database for graft vs. host disease
Every month we try and update this database with for graft vs. host disease cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Cellular Therapy With Cord Blood Cells | NCT00427557 | Multiple Myelom... Leukemia Lymphoma | Fludarabine Melphalan Umbilical Cord ... Rituximab Peripheral Bloo... | - 80 Years | M.D. Anderson Cancer Center | |
| Stem Cell (Modified Bone Marrow) Transplantation in HIV-Infected Patients With Blood Cancer | NCT00005785 | Hematologic Neo... HIV Infection | GCSF Mobilized ... | - | National Institutes of Health Clinical Center (CC) | |
| Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow | NCT00003838 | Myeloproliferat... Acute Myelogeno... Chronic Myeloge... Myelodysplastic... Acute Lymphobla... | T-cell replete ... Methotrexate Cyclosporine G-CSF | 2 Years - 80 Years | National Institutes of Health Clinical Center (CC) | |
| Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies | NCT03717480 | Hematologic Mal... | ClinicMACs | 18 Years - 65 Years | Dana-Farber Cancer Institute | |
| Cellular Therapy With Cord Blood Cells | NCT00427557 | Multiple Myelom... Leukemia Lymphoma | Fludarabine Melphalan Umbilical Cord ... Rituximab Peripheral Bloo... | - 80 Years | M.D. Anderson Cancer Center | |
| Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants | NCT00001830 | Chronic Lymphoc... Graft vs Host D... Hodgkin's Disea... Multiple Myelom... Non Hodgkin's L... | Th2 cells in al... Th2 Cells | 12 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Safety Study of MultiStem® in Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplasia | NCT00677859 | Hematologic Mal... | MultiStem® MultiStem® | 18 Years - 65 Years | Healios K.K. | |
| Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow | NCT00003838 | Myeloproliferat... Acute Myelogeno... Chronic Myeloge... Myelodysplastic... Acute Lymphobla... | T-cell replete ... Methotrexate Cyclosporine G-CSF | 2 Years - 80 Years | National Institutes of Health Clinical Center (CC) | |
| HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological Malignancies | NCT00001748 | Graft vs Host D... Hematologic Neo... Lymphoma Myelodysplastic... Myeloid Leukemi... | Peripheral bloo... | - | National Institutes of Health Clinical Center (CC) | |
| Donor Dendritic Cells And Donor Lymphocytes in Patients With Relapsed Hematologic Malignancies After Allogeneic Transplant | NCT00476177 | Hematologic Mal... | Infusion of don... Infusion of don... | 18 Years - | Dana-Farber Cancer Institute | |
| The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers | NCT00001873 | Chronic Lymphoc... Graft vs Host D... Hematologic Neo... Multiple Myelom... Myelodysplastic... | Isolex 300i plu... | 10 Years - 55 Years | National Institutes of Health Clinical Center (CC) | |
| Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies | NCT03717480 | Hematologic Mal... | ClinicMACs | 18 Years - 65 Years | Dana-Farber Cancer Institute | |
| Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow | NCT00003838 | Myeloproliferat... Acute Myelogeno... Chronic Myeloge... Myelodysplastic... Acute Lymphobla... | T-cell replete ... Methotrexate Cyclosporine G-CSF | 2 Years - 80 Years | National Institutes of Health Clinical Center (CC) | |
| Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies | NCT00473551 | Leukemia Lymphoma Myeloma | Rituximab Cyclophosphamid... Fludarabine Mesna Radiation Treat... Stem Cell Trans... Sirolimus Anti-third Part... | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Safety Study of MultiStem® in Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplasia | NCT00677859 | Hematologic Mal... | MultiStem® MultiStem® | 18 Years - 65 Years | Healios K.K. | |
| Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants | NCT00001830 | Chronic Lymphoc... Graft vs Host D... Hodgkin's Disea... Multiple Myelom... Non Hodgkin's L... | Th2 cells in al... Th2 Cells | 12 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia | NCT00001623 | Graft vs Host D... Hematologic Neo... Leukemia Multiple Myelom... Myelodysplastic... | Allogeneic Bone... | 10 Years - 55 Years | National Institutes of Health Clinical Center (CC) | |
| Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies | NCT03717480 | Hematologic Mal... | ClinicMACs | 18 Years - 65 Years | Dana-Farber Cancer Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
